Search results for: Value-Based Pricing
Filter search results
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
…when appraising the value of a health technology. OHE has contributed to this debate with its own Whitepaper arguing for a broader perspective on value. The debate A key debate…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
…(or even more importantly the unrealised potentialto treat multiple indications), the way we pay for those medicines becomes critical in making sure we can benefit from them. “Indication-based pricing” (IBP)…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
…London: Office of Health Economics. Available at: https://www.ohe.org/publications/who-technical-report-pricing-cancer-medicines-missing-central-role-hta-and-value Danzon, Towse and Mestre-Ferrandiz (2015). Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context” Health Econ. 24: 294–301. See OHE blog at https://www.ohe.org/news/pricing-variations-within-and-across-countries-gauging-efficiency …
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight to cost-offsets outside the…
Do child QALYs = adult QALYs? Five reasons why they might not
4 February 2020
…life for adults apply here too: what stated preference method is best? What sub-set of states to value? How to model the values? But aside from these common issues there…
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?
1 July 2021
…of the use of early HTA to set value-based prices instead of cost-based prices, so that vaccines that provide more benefit get relatively higher prices. It is important to reward…
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
…rare diseases, international collaborations, and consistent patient involvement can help mitigate these barriers. Priority value elements Based on the survey results and expert advisory group input, the prioritised value elements…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…– value that extends well beyond preserving the health of the vaccinated individual and avoiding the costs associated with COVID-19 disease. These broader value aspects are by no means unique…